PSILETF / FundAdvisorShares Psychedelics ETF
Verdicts genuinely change. Free email alert the moment PSIL's does — no target price to set, unlike "Alert" above.
Whether this fund clears the published standards, and the filings behind that answer. The screen runs first and nothing on the trading side can override it.
Structure, momentum, positioning and levels. Separate from the Sharia verdict above, which this side never overrides.
AdvisorShares Psychedelics ETF · AdvisorShares Trust
32 holdings · as of 2026-06-30 (4.1 months ago) The fund may have traded since. SEC Form N-PORT is filed quarterly and lags the period it covers, so these are the most recent holdings on file, not the fund’s holdings today.
This fund holds short positions, so exposure is counted gross — long and short both count as exposure rather than netting off, and the weights below therefore sum to 103% of net assets rather than 100%. Shares of the portfolio are shown as shares of that gross exposure.
NON-COMPLIANT At least 26.65% of portfolio weight is in non-compliant holdings — already over the 5% threshold, so the verdict is settled whatever the unmatched 50% turns out to be. Matching more holdings can only raise this share, never lower it.
32 holdings, 16 matched (51% of weight). Portfolio as of 2026-06-30, filed 2026-08-21. Source: SEC Form N-PORT.
18.79% of this portfolio’s income is non-permissible — weighted across holdings, computed over 32% of portfolio weight (9 of 32 holdings). The common approach purifies that proportion of income received — dividends — not of the position’s value. We report the ratio; what to do with it is a question for your own scholar.
Portfolio shares are withheld: coverage is below the floor needed to state one. The holdings themselves are below, because the names are evidence you can check.
All holdings (32)
| Holding | Status | Weight | Every methodology, and the debt ratio behind it |
|---|---|---|---|
| DEFINIUM THERAPEUTICS INC | UNSCREENED | 12.85% | no in-house ratios for this holding |
| COMPASS PATHWAYS PLC | UNSCREENED | 11.45% | no in-house ratios for this holding |
| ATAI ATAIBECKLEY INC | NON_COMPLIANT | 10.47% | AAOIFI0.9% Usmani9.4% Dow Jones Islamic2.0% S&P Shariah2.5% MSCI Islamic9.4% MSCI Islamic M-Series2.5% FTSE Shariah8.7% |
| RLMD RELMADA THERAPEUTICS INC | NON_COMPLIANT | 6.84% | AAOIFI0.0% Usmani0.0% Dow Jones Islamic0.0% S&P Shariah0.0% MSCI Islamic0.0% MSCI Islamic M-Series0.0% FTSE Shariah0.0% |
| NRXP NRX PHARMACEUTICALS INC | COMPLIANT | 6.07% | AAOIFI0.0% Usmani0.0% Dow Jones Islamic0.0% S&P Shariah0.0% MSCI Islamic0.0% MSCI Islamic M-Series0.0% FTSE Shariah0.0% |
| NBIX NEUROCRINE BIOSCIENCES INC | COMPLIANT | 4.38% | AAOIFI2.9% Usmani8.6% Dow Jones Islamic3.4% S&P Shariah3.5% MSCI Islamic8.6% MSCI Islamic M-Series3.5% FTSE Shariah0.0% |
| CYBIN INC | UNSCREENED | 4.35% | no in-house ratios for this holding |
| GH RESEARCH PLC | UNSCREENED | 4.31% | no in-house ratios for this holding |
| ALKS ALKERMES PLC | COMPLIANT | 4.30% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| ALTO NEUROSCIENCE INC | UNSCREENED | 4.20% | no in-house ratios for this holding |
| ABBV ABBVIE INC | COMPLIANT | 4.14% | AAOIFIpass Usmanifail Dow Jones Islamicpass S&P Shariahpass MSCI Islamicfail MSCI Islamic M-Seriespass FTSE Shariahfail |
| BLACKROCK TREASURY TRUST | UNSCREENED | 3.97% | no in-house ratios for this holding |
| BRIGHT MINDS BIOSCIENCES INC | UNSCREENED | 3.84% | no in-house ratios for this holding |
| JNJ JOHNSON & JOHNSON | COMPLIANT | 3.61% | AAOIFI7.6% Usmani24.4% Dow Jones Islamic10.9% S&P Shariah11.7% MSCI Islamic24.4% MSCI Islamic M-Series11.7% FTSE Shariah24.4% |
| DREY INST PREF GOV MM-M | UNSCREENED | 3.10% | no in-house ratios for this holding |
| SUPN SUPERNUS PHARMACEUTICALS INC | COMPLIANT | 2.89% | AAOIFIpass Usmanipass Dow Jones Islamicpass S&P Shariahpass MSCI Islamicpass MSCI Islamic M-Seriespass FTSE Shariahpass |
| NEUP NEUPHORIA THERAPEUTICS INC | NON_COMPLIANT | 2.49% | AAOIFI0.0% Usmani0.0% Dow Jones Islamic0.0% S&P Shariah0.0% MSCI Islamic0.0% MSCI Islamic M-Series0.0% FTSE Shariah0.0% |
| STIM NEURONETICS INC | NON_COMPLIANT | 2.17% | AAOIFI39.4% Usmani65.8% Dow Jones Islamic60.7% S&P Shariah73.2% MSCI Islamic65.8% MSCI Islamic M-Series73.2% FTSE Shariah46.8% |
| QUANTUM BIOPHARMA LTD | UNSCREENED | 1.66% | no in-house ratios for this holding |
| OPTH OPTIMI HEALTH CORP | NON_COMPLIANT | 1.18% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| KTTA PASITHEA THERAPEUTICS CORP | NON_COMPLIANT | 1.09% | AAOIFI0.0% Usmani0.0% Dow Jones Islamic0.0% S&P Shariah0.0% MSCI Islamic0.0% MSCI Islamic M-Series0.0% FTSE Shariah0.0% |
| SILO SILO PHARMA INC | NON_COMPLIANT | 1.06% | AAOIFI0.0% Usmani0.0% Dow Jones Islamic0.0% S&P Shariah0.0% MSCI Islamic0.0% MSCI Islamic M-Series0.0% FTSE Shariah0.0% |
| PBM PSYENCE BIOMEDICAL LTD | NON_COMPLIANT | 0.84% | AAOIFIfail Usmanifail Dow Jones Islamic— S&P Shariah— MSCI Islamicfail MSCI Islamic M-Series— FTSE Shariahfail |
| IXHL INCANNEX HEALTHCARE INC | NON_COMPLIANT | 0.52% | AAOIFI9.3% Usmani5.3% Dow Jones Islamic7.9% S&P Shariah0.5% MSCI Islamic5.3% MSCI Islamic M-Series0.5% FTSE Shariah5.2% |
| NUMIF NUMINUS WELLNESS INC | COMPLIANT | 0.47% | AAOIFI19.4% Usmani103.1% Dow Jones Islamic17.2% S&P Shariah11.3% MSCI Islamic54.2% MSCI Islamic M-Series11.3% FTSE Shariah54.2% |
| IGC PHARMA INC | UNSCREENED | 0.42% | no in-house ratios for this holding |
| VISTAGEN THERAPEUTICS INC | UNSCREENED | 0.22% | no in-house ratios for this holding |
| ENVERIC BIOSCIENCES INC | UNSCREENED | 0.11% | no in-house ratios for this holding |
| CLEARMIND MEDICINE INC | UNSCREENED | 0.01% | no in-house ratios for this holding |
| QUANTUM BIOPHARMA | UNSCREENED | 0.00% | no in-house ratios for this holding |
| SAGE THERAPEUTICS INC | UNSCREENED | 0.00% | no in-house ratios for this holding |
| UNBUZZD WELLNESS INC | UNSCREENED | 0.00% | no in-house ratios for this holding |
The published standards disagree about this fund by 5 points of portfolio weight — 15.5% of it passes AAOIFI, 10.9% passes Usmani. Which number is yours depends on which standard you follow.
These bars are the financial-ratio result under each standard — debt, receivables and interest income. They do not screen what the business does, so a holding can pass every ratio here and still be questionable or non-compliant on activity. The blended verdict above accounts for both.
ratios pass on 15.5% ratios fail on 25.5% 62.0% not rated under AAOIFI
ratios pass on 10.9% ratios fail on 36.2% 56.0% not rated under Usmani
ratios pass on 15.5% ratios fail on 29.6% 57.9% not rated under Dow Jones Islamic
ratios pass on 15.5% ratios fail on 29.1% 58.4% not rated under S&P Shariah
ratios pass on 10.9% ratios fail on 36.2% 56.0% not rated under MSCI Islamic
ratios pass on 15.5% ratios fail on 29.1% 58.4% not rated under MSCI Islamic M-Series
ratios pass on 10.9% ratios fail on 36.2% 56.0% not rated under FTSE Shariah
16 of 32 listed holdings carry our own per-methodology verdicts (53% of weight). The rest hold a provider verdict with no methodology breakdown, and are counted as rated by none. Of those, 11 (39% of weight) also carry the underlying debt ratio; the rest show a verdict without the figure behind it.
| Non-compliant holding | Weight |
|---|---|
| ATAI ATAIBECKLEY INC | 10.47% |
| RLMD RELMADA THERAPEUTICS INC | 6.84% |
| NEUP NEUPHORIA THERAPEUTICS INC | 2.49% |
| STIM NEURONETICS INC | 2.17% |
| OPTH OPTIMI HEALTH CORP | 1.18% |
| KTTA PASITHEA THERAPEUTICS CORP | 1.09% |
| SILO SILO PHARMA INC | 1.06% |
| PBM PSYENCE BIOMEDICAL LTD | 0.84% |
| IXHL INCANNEX HEALTHCARE INC | 0.52% |
Methodology breakdown computing — it will appear here on its own.
Trade setup
Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.
Why this signal?
The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.
AdvisorShares Psychedelics ETF (PSIL) is currently considered not halal (non-compliant), per our own look-through to its filed holdings. See its filed holdings and the weight breakdown below for the reasoning.
🕌 In-house Compliance Research
Computing the full ratio and business-activity breakdown for PSIL — this runs off the critical path so the page paints first. It will appear here on its own.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
Price Forecast
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
Technical Summary
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Every indicator, and what it reads
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 43.40 | NEUTRAL |
| Stochastic %K (14) | 53.33 | NEUTRAL |
| CCI (20) | 32.94 | NEUTRAL |
| Williams %R (14) | -46.67 | NEUTRAL |
| MACD (12,26,9) | 0.21 | BUY |
| ROC (10) | 5.53 | BUY |
| Momentum (10) | 1.10 | BUY |
| EMA (10) | 21.06 | SELL |
| SMA (10) | 20.96 | BUY |
| EMA (20) | 21.32 | SELL |
| SMA (20) | 20.92 | BUY |
| EMA (30) | 21.74 | SELL |
| SMA (30) | 21.71 | SELL |
| EMA (50) | 22.30 | SELL |
| SMA (50) | 23.09 | SELL |
| EMA (100) | 22.34 | SELL |
| SMA (100) | 23.24 | SELL |
| EMA (200) | 20.65 | BUY |
| SMA (200) | 20.74 | BUY |
About AdvisorShares Psychedelics ETF
The fund is an actively managed ETF that seeks to achieve its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that derive at least 50% of their net revenue from or devote 50% of their assets to psychedelic drugs and derivatives that have economic characteristics similar to such securities. The fund primarily invests in publicly listed life sciences companies focused on psychedelic medicines as well as other companies with activities in the psychedelics business. The fund is non-diversified.
Background via Yahoo Finance — informational, not part of the verdict.
Good setup, solid confluence
SMC — Top Down
Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | BULLISH | 41 |
| 🕐 1H | BULLISH | 45 |
| ⏱ 15-Min | BULLISH | 130 |
| ⏲ 5-Min | BEARISH | 234 |
Momentum & Volume
Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.
Peer Movement
How the rest of the sector moved over the same window. Context for a price move, never a cause of one.
Peer movement computing — it will appear here on its own.
Before you act on this
The questions worth asking about any verdict on this page, answered plainly.
Is a fund screened on its name?
No. HTR reads the fund's filed holdings and screens each one, then reports the result by weight. A fund marketed as Islamic still gets the same look-through as any other.
What does unrated weight mean?
It is the share of the fund whose holdings HTR cannot cover far enough to rate. It is reported as unrated rather than counted as compliant, because a holding nobody screened should not look like one that passed.
Does the issuer's board make it compliant?
It matters, and it is noted, but it does not replace the look-through. The board's judgement and the holdings screen are shown separately so you can see when they agree and when they do not.
How often is this re-screened?
When the fund files new holdings, and on a rolling basis besides. The date on the verdict above is the last time this fund was actually recomputed.
Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.
Compare with
Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.
Peer screening computing — it will appear here on its own.
Insider Activity (90d)
Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.
NO DATA 0 buys · 0 sells
COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE
The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.
NEUTRAL report date 2026-10-27 · Asset managers net 923449 (+22072)
AI Summary
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.